Диссертация (Способы коррекции ранних механизмов канцерогенеза в органах репродуктивной системы), страница 34

CancerEpidemiol Biomarkers Prev. 2006; 15(6):1229-31.235.Plu-Bureau G., Thalabard J.C., Sitruk-Ware R., Asselain B.,Mauvais- Jarvis P.M. Cyclical mastalgia as a marker of breast cancersusceptibility: results of a case- control study among French women. BrJ Cancer 1992; 65:945–9.207236.Pungal A., Balan R., Cotuţiu C. Hormone receptors and markers inendometrial hyperplasia.

Immunohistochemical study. Rev Med ChirSoc Med Nat Iasi. 2010; 114(1):180-4.237.Qian J, Wollan P, Bostwick DG. The extent and multicentricity ofhigh-grade prostatic intraepithelial neoplasia in clinically localizedprostatic adenocarcinoma. Hum Pathol. 1997; 28:143–148.238.QuddusMR,SungCJ,ZhengW,LauchlanSC.p53immunoreactivity in endometrial metaplasia with dysfunctional uterinebleeding. Histopathology 1999; 35: 44–49.239.Radpour R., Barekati Z., Kohler C., Schumacher M.M.,Grussenmeyer T., Jenoe P., Hartmann N., Moes S., Letzkus M., BitzerJ., Lefkovits I., Staedtler F., Zhong X.Y. Integrated epigenetics of humanbreast cancer: synoptic investigation of targeted genes, microRNAs andproteins upon demethylation treatment. PLoS One.

2011; 6(11): e27355.240.Raina K., Singh R.P., Agarwal R., Agarwal C. Oral grape seedextract inhibits prostate tumor growth and progression in TRAMP mice.Cancer Res. 2007; 67:5976–82.241.Rajamanickam S., Agarwal R. Natural products and colon cancer:Current status and future prospects. Drug Dev Res. 2008; 69:460–71.242.Rank KB, Evans DB, Sharma SK. The N-terminal domains ofcyclin-dependent kinase inhibitory proteins block the phosphorylation ofcdk2/Cyclin E by the CDK-activating kinase.

Biochem Biophys ResCommun. 2000; 271(2):469-73.243.Rasheed Z., Kowalski J., Smith B. et al. Concise review: Emergingconcepts in clinical targeting of cancer stem cells // Stem Cells. 2011; 29(6): 883–7.244.Reed G.A., Arneson D.W., Putnam W.C., Smith H.J., Gray J.C.,Sullivan D.K., Mayo M.S., Crowell J.A., Hurwitz A. Single-dose andmultiple-doseadministration208ofindole-3-carbinoltowomen:pharmacokinetics based on 3,3'-diindolylmethane. Cancer EpidemiolBiomarkers Prev.

2006; 15(12):2477-81.245.Reed G.A., et al. A phase I study of indole-3-carbinol in women:tolerability and effects. Cancer Epidemiol Biomarkers Prev., 2005, 7,1953-60.246.Rice J.C., Ozcelik H., Maxeiner P., Andrulis I., Futscher B.W.Methylation of the BRCA1 promoter is associated with decreasedBRCA1mRNAlevelsinclinicalbreastcancerspecimens.Carcinogenesis 2000, 21: 1761–1765.247.Rieder J., Marth C., Totzke G., Smolny M., Seibel M., HoffmannG.

Different patterns of inducible nitric oxide synthase gene expressionin ovarian carcinoma cell lines. Anticancer Research, vol. 20, no. 5, pp.3251–3258, 2000.248.Risbridger G.P., Bianco J.J., Ellem S.J., McPherson S.J. Oestrogensand prostate cancer. Endocrine-Related Cancer. 2003. 10(2):187-91.249.Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W,Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV,Schillaci R.

TNF alpha acting on TNFR1 promotes breast cancer growthvia p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.Exp Cell Res. 2008; 314(3):509-529.250.Robertson K.D. DNA methylation, methyltransferases, and cancer.Oncogene 2001, 20(24):3139-3155.251.Rowlands IJ, Nagle CM, Spurdle AB, Webb PM. Gynecologicalconditions and the risk of endometrial cancer. Gynecol Oncol. 2011;123(3):537-41.252.Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F.,Schalken J. Molecular genetics and epidemiology of prostate carcinoma.Endocr Rev.

1999; 20(1):22-45.209253.Saavedra K.P., Brebi P.M., Roa J.C. Epigenetic alterations inpreneoplastic and neoplastic lesions of the cervix. Clin Epigenetics.2012; 4:13.254.Scaffidi P., Misteli T. Cancer epigenetics: from disruption ofdifferentiation programs to the emergence of cancer stem cells. ColdSpring Harb Symp Quant Biol. 2010;75:251-8.255.Scheel C., Weinberg R.A.

Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin CancerBiol. 2012; 22(5-6):396-403.256.Schiff R., Massarweh S.A., Shou J., et al. Crosstalk betweenestrogen receptor and growth factor pathways as a molecular target forovercoming endocrine resistance. Clin Cancer Res, 2004; 10, 331-6.257.Schiffman M., Herrero R., Desalle R., et al. The carcinogenicity ofhuman papillomavirus types reflects viral evolution.

Virology 2005; 337:76–84.258.Schindler C., Darnell J.E. Transcriptional Responses to PolypeptideLigands: The JAK-STAT Pathway. Annual Review of Biochemistry1995; 64: 621–652.259.Schnitt S. J., et al. Benign breast disease and breast cancer risk:morphology and beyond. Am J Surg Pathol. 2003; 27(6):836-41.260.Semov A., Iourtchenco L., Liu L.F., Li S., Xu Y., Su X., MuyjnekE., Kiselev V., Alakhov V. Diindolilmethane (DIM) selectively inhibitscancer stem cells. Biochem Biophys Res Commun. 2012; 424(1):45-51.261.Sepkovic D.W., Pagan D.V., Stein J., Carlisle A.D., Ksieski H.B.,Auborn K., Nyirenda T., Bradlow H.L. Evaluation of 3,3'diindolylmethane with gardasil quadrivalent HPV vaccine in K14HPV16-transgenic mice cervical histology.

In Vivo. 2013; 27(3):299304.210262.Sepkovic D.W., Stein J., Carlisle A.D., Ksieski H.B., Auborn K.,Bradlow H.L. Diindolylmethane inhibits cervical dysplasia, altersestrogen metabolism, and enhances immune response in the K14-HPV16transgenic mouse model. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2957-64.263.Shao W., Brown M. Advances in estrogen receptor biology:prospects for improvements in targeted breast cancer therapy. BreastCancer Res. 2004; 6(1):39-52.264.Sharifi N., Kawasaki B.T., Hurt E.M., Farrar W.L., Lawson D.A.,Witte O.N. Stem cells in prostate cancer: resolving the castrate-resistantconundrum and implications for hormonal therapy.Cancer Biol Ther.2006 Aug;5(8):901-906; Lawson DA, Witte ON. Stem cells in prostatecancer initiation and progression // J.

Clin. Invest. – 2007. – Vol.117, No.8. – Р. 2044-2050.265.Sharma G., Tyagi A.K., Singh R.P., Chan D.C., Agarwal R.Synergistic anti-cancer effects of grape seed extract and conventionalcytotoxic agent doxorubicin against human breast carcinoma cells.Breast Cancer Res Treat. 2004; 85:1–12.266.Sherr C.J. G1 phase progression: cycling on cue. Cell 1994; 79, 551.267.Shi A.-M., Tao Z.-Q., Li H., Wang Y.-Q., Zhao J. Cancer stem cellstargeting agents – a review. Eur Rev Med Pharmacol Sci 2015; 19 (21):4064-4067.268.Shin M, Takayama H, Nonomura N, Wakatsuki A, Okuyama A,Aozasa K.

Extent and zonal distribution of prostatic intraepithelialneoplasia in patients with prostatic carcinoma in Japan: Analysis ofwhole-mounted prostatectomy specimens. Prostate. 2000; 42:81–87.269.Shubina AN, Egorova AA, Baranov VS, Kiselev AV. Recentadvances in gene therapy of endometriosis. Recent Pat DNA Gene Seq.2013; 7(3):169-78.211270.Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M.,Khwaja S.I., Ahmad N., Cui H., Mousa S.A., Mukhtar H. Introducingnanochemoprevention as a novel approach for cancer control: proof ofprinciple with green tea polyphenol epigallocatechin-3-gallate. CancerRes. 2009 Mar 1;69(5):1712-6.271.Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics.

CA CANCERJ CLIN 2014; 64:9–29.272.Sieja K., Stanosz S., Glowińska N. Histamine and epidermal growthfactor in women with fibrocystic changes of the breast. Breast. 2003;12(2):99-103.273.Silverberg S.G., Kurman R.J., Nogales F., Mutter G.L., Kubik-Huch R.A., Tavassoli F.A. Tumors of the uterine corpus A.T. Fattaneh,P. Devilee (Eds.), World Health organization classification of tumors,pathology & genetics, tumors of the breast and female genital organs,IARC Press, Lyon (2003), pp. 220–230.274.Singh P., Bast F. Screening of multi-targeted natural compounds forreceptor tyrosine kinases inhibitors and biological evaluation on cancercell lines, in silico and in vitro.

Med Oncol. 2015; 32(9):233.275.Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus typedistribution in invasive cervical cancer and high-grade cervical lesions:a meta-analysis update. Int J Cancer. 2007; 121: 621–32.276.Sporn M.B., et al. Prevention of chemical carcinogenesis by vitaminA and its synthetic analogs (retinoids). Fed Proc. 1976; 35: 1332-1338.277.Staff S., Isola J., Tanner M. (2003) Haplo-insufficiency of BRCA1in sporadic breast cancer. Cancer Res 63: 4978–4983.278.Stearns M.E., Wang M. Synergistic effects of the green tea extractepigallocatechin-3-gallate and taxane in eradication of malignant humanprostate tumors.